Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991579 | 0.79 | HSD11B1 (0.38) | HSD11B1MAPTALDH1A1MEN1GAA | |
| SCHEMBL2991428 | 0.78 | HSD11B1 (0.39) | HSD11B1MAPTALDH1A1NPSR1GAA | |
| SCHEMBL2995518 | 0.77 | HSD11B1 (0.37) | HSD11B1TDP1ALDH1A1NPSR1MEN1 | |
| SCHEMBL22792062 | 0.75 | HSD11B1 (0.46) | HSD11B1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2987303 | 0.71 | ALDH1A1 (0.44) | HSD11B1MAPTALDH1A1MEN1GAA | |
| SCHEMBL2991668 | 0.69 | HSD11B1 (0.38) | HSD11B1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL15206947 | 0.68 | HSD11B1 (0.69) | HSD11B1MAPTALDH1A1MEN1GAA | |
| SCHEMBL12248497 | 0.67 | RECQL (0.44) | TDP1ALDH1A1DUTMEN1KMT2A | |
| SCHEMBL2994931 | 0.67 | MEN1 (0.34) | HSD11B1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6903823 | 0.66 | NR3C2 (0.53) | ATMGLAMAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776897-B2 | such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance | ASTELLAS PHARMA INC. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885ATM 2426/4885GLA 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.